Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 18 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

11%

2 trials in Phase 3/4

Results Transparency

36%

4 of 11 completed with results

Key Signals

4 with results100% success

Data Visualizations

Phase Distribution

8Total
Not Applicable (6)
P 3 (2)

Trial Status

Completed11
Recruiting4
Active Not Recruiting2
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT07519876RecruitingPrimary

Pulmonary Embolism and Right-to-Left Shunts

NCT07491094Not Yet Recruiting

Repeated Examinations for Typing Pulmonary Embolism

NCT07452991Not ApplicableRecruitingPrimary

ULTRAsound-assisted Catheter-guided Thrombolysis for Intermediate-high Risk Patients With PE

NCT07455253Active Not Recruiting

Effectiveness and Cost-effectiveness of VTE Prevention Strategies in Gynecological Surgery

NCT07342374Not ApplicableCompleted

Repositioning the Bolus Tracking ROI to the Superior Vena Cava in CTPA Facilitates Contrast Volume Reduction

NCT07009301CompletedPrimary

Pulmonary Embolism Following Viper's Bites: A Case Report

NCT06946732Not ApplicableRecruitingPrimary

Acostream Use in Patients With High Risk and Intermediate-risk Acute Pulmonary Embolism

NCT06930937Not ApplicableCompleted

To Compare and Evaluate the Oral Bioavailability of Edoxaban 60 mg Film Coated Tablet With That of Lixiana® 60 mg Filmtabletten (Film Coated Tablet) (Edoxaban) in Healthy, Adult, Human Subjects Under Fasting Conditions

NCT06596941Active Not Recruiting

Ultrasound Assessment of Isolated Distal Deep Vein Thrombosis

NCT02156401Recruiting

VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE

NCT02744092Not ApplicableCompleted

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

NCT03595891CompletedPrimary

The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the Lung

NCT02210819Completed

Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy

NCT02438462CompletedPrimary

Soluble Fibrin for Diagnosing Pulmonary Embolism

NCT02523937CompletedPrimary

Evaluation of Soluble Fibrin in Thrombosis Exclusion

NCT02073682Phase 3Completed

Cancer Venous Thromboembolism (VTE)

NCT00986154Phase 3Completed

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

NCT00358735Not ApplicableCompleted

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

Showing all 18 trials

Research Network

Activity Timeline